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The therapeutic potential of tocotrienol, an extract of vitamin E with anti-cancer properties, is hampered by its
failure to specifically reach tumors after intravenous administration,without secondary effects onnormal tissues.
We hypothesize that the encapsulation of tocotrienol-rich fraction (TRF) within vesicles bearing transferrin,
whose receptors are overexpressed on many cancer cells, could result in a selective delivery to tumors after
intravenous administration. The objectives of this study are therefore to prepare and characterize transferrin-
targeted vesicles encapsulating TRF, and to evaluate their therapeutic efficacy in vitro and in vivo.
The entrapment of TRF in transferrin-bearing vesicles led to a 3-fold higher TRF uptake and more than 100-fold
improved cytotoxicity in A431 (epidermoid carcinoma), T98G (glioblastoma) and A2780 (ovarian carcinoma)
cell lines compared to TRF solution. The intravenous administration of TRF encapsulated in transferrin-bearing
vesicles led to tumor regression and improvement of animal survival in a murine xenograft model, contrary to
that observed with controls. The treatment was well tolerated by the animals.
This work corresponds to the first preparation of a tumor-targeted delivery system able to encapsulate
tocotrienol. Our findings show that TRF encapsulated in transferrin-bearing vesicles is a highly promising
therapeutic system, leading to tumor regression after intravenous administration without visible toxicity.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
An extract of vitamin E, tocotrienol, has recently gained considerable
attention for its tumor suppressive effects on many cancers, including
prostate, breast, liver and lung cancers [1]. Tocotrienol has been
reported to exert its anti-cancer effect through mechanisms such as
decrease of oxidative stress, activation of p53, modulation of Bax/Bcl-2
ratio and induction of apoptosis. It also inhibits several enzymes related
to cancer cell proliferation, such as DNA polymerase and telomerase,
and NF-κB activation pathway, leading to potentiation of apoptosis.
Tocotrienolwas alsoable todownregulate the expressionof thevascular
endothelial growth factor (VEGF) receptor and to block intracellular
VEGF signaling, thus resulting in the inhibition of angiogenesis [2–4].
However, its therapeutic potential is currently limited by its failure
to reach tumors at high concentrations without secondary effects on
normal tissues.Given the anti-proliferative properties of tocotrienol, it is
crucial to deliver the therapeutic drug specifically to its site of action.
As iron is essential for tumor cell growth and can be effectively
carried to tumors by using transferrin receptors, we hypothesize that
the encapsulation of tocotrienol within vesicles bearing transferrin
could result in a selective delivery of tocotrienol to tumors after
intravenous administration, leading to an improved therapeutic
efficacy. Transferrin receptor is an attractive target for selective
receptor-mediated gene delivery to tumors because it is over-
expressed in a high percentage of human cancers, including ovarian,
breast, colon cancers and glioblastoma cell lines [5,6]. Although
transferrin receptors are also expressed in some rapidly dividing
healthy tissues, the combination of active targeting, based on the use
of ligands, and passive targeting, based on the accumulation of
particulate delivery systems due to enhanced permeability and
retention [7], should provide a tumor-selective targeting strategy.
Transferrin (Tf) has previously been used successfully as a tumor-
targeting ligand for several drug delivery systems [5,8–10].
The objectives of this study are therefore to prepare and
characterize transferrin-bearing vesicles encapsulating TRF and to
evaluate their therapeutic efficacy in vitro and in vivo.
2. Materials and methods
2.1. Cell lines and reagents
Palm oil and Tocotrienol Rich Fraction (TRF), a mixture of 17.6% α-
tocotrienol, 23.1%γ-tocotrienol, 15.1% δ-tocotrienol, 15.3%α-tocopherol,
and other tocotrienol-related compounds, were kindly donated by Dr.
Nor Aini Idris and Dr. Abdul Gapor from the Malaysian Palm Oil Board
(Kuala Lumpur, Malaysia). Solulan C24 was purchased from Amerchol
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(Edison, NJ). Vectashield® mounting medium with propidium iodide
was obtained from Vector Laboratories (Peterborough, UK). Isopropanol
and dimethylsulfoxide were purchased from Merck (Nottingham, UK).
A431 epidermoid carcinoma, T98G glioblastoma and A2780 ovarian
carcinoma were obtained from the European Collection of Cell Cultures.
Tissue culture media were purchased from Invitrogen (Paisley, UK). All
other chemicals came from Sigma (Poole, UK).
2.2. Preparation and characterization of transferrin-bearing vesicles
encapsulating TRF
Transferrin (Tf)-bearing vesicles encapsulating TRF were prepared
by modification of a previously described method [9,10]. Control
vesicles encapsulating TRF were prepared by shaking a mixture of
Span 60 (65 mg), cholesterol (58 mg), Solulan C24 (54 mg) in TRF
solution (0.5 mg/mL, 2 mL, prepared in PBS, palm oil or dimethylsulf-
oxide) at 60 °C for 1 h, followed by probe sonication (Soniprep 150,
Fisher Scientific) for 4 minwith the instrument set at 75% of itsmaximal
capacity. Transferrin (6 mg) was linked to the vesicles (2 mL) by cross-
linking with dimethylsuberimidate as previously described [9]. Free
drugwas removed by ultracentrifugation as described [9]. Vesicleswere
visualized by transmission electron microscopy on a LEO 912 energy
filtering electronmicroscope as described [9]. TRF loading of the vesicles
was measured spectrofluorometrically (λex 295 nm, λem 325 nm, using
a Cary eclipse spectrofluorometer, Varian) after disruption of vesicles
with isopropanol. The amount of conjugated transferrin was deter-
mined using the Lowry method as described [9]. Vesicle size and zeta
potential were respectively measured by photon correlation spectro-
scopy and laser Doppler electrophoresis on a Zetasizer Nano-ZS
(Malvern Instruments, Malvern, UK).
2.3. In vitro biological characterization
2.3.1. Cell culture
A431, T98G and A2780 cell lines were grown as monolayers in
DMEM (A431 and T98G) or RPMI (A2780) medium supplemented
with 10% (v/v) fetal bovine serum, 1% (v/v) L-glutamine and 0.5% (v/v)
penicillin–streptomycin. Cells were cultured at 37 °C in a humid
atmosphere of 5% CO2.
2.3.2. Cellular uptake of TRF entrapped in Tf-bearing vesicles
A431, T98G and A2780 cells (4×103 cells/well in 96-well plates
seeded 72 h prior treatment) were incubated for 96 hwith TRF (10 µg /
well) formulated as Tf-vesicles, control vesicles or as free drug. After the
incubation, cells were washed twice with PBS and lysed. The amount of
TRF in the cell lysate was assessed by fluorescence spectrophotometry
(λex=295 nm, λem=325 nm).
Imaging of TRF cellular uptake was carried out using confocal
microscopy. A431, T98G and A2780 cells were grown on microscope
slides (0.6×106 cells/90-mm Petri dish) for 24 h. The cells were then
treated for 4 h with 50 µg TRF either entrapped in Tf-vesicles, control
vesicles or in solution. They were then washed with PBS and fixed in
methanol for 10 min.Upon stainingof the nucleiwithpropidium iodide,
cells were examined using a Leica SP-5 confocal laser scanning
microscope (λex=535 nm and λem=615 nm for stained nuclei, λex=
295 nm and λem=325 nm for TRF).
2.3.3. Cytotoxicity assay
Anti-proliferative activity of transferrin- and control vesicles
entrapping TRF was compared with TRF solution in A431, T98G and
A2780 cell lines. Cells (2×103 cells per well in 96-well plates seeded
72 h prior treatment) were incubated for 72 h with TRF formulations
at final concentrations of 1×10−7 to 1×102 µg/mL. Cytotoxicity was
evaluated by measurement of the growth inhibitory concentration for
50% of the cell population (IC50) in a standard MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] assay [11].
Dose–response curves were fitted to percentage absorbance values to
obtain IC50 values (three independent experiments with n=5 for
each concentration level).
2.4. In vivo study
2.4.1. Animals
Female immunodeficient BALB/c mice (initial mean weight 20 g)
housed in groups of five at 19 °C to 23 °C with a 12-hour light–dark
cycle were fed a conventional diet (Rat and Mouse Standard
Expanded, B&K Universal, Grimston, United Kingdom) with mains
water ad libitum. Experimental work was carried out in accordance
with UK Home Office regulations and approved by the local ethics
committee.
2.4.2. In vivo tumoricidal activity
Tumors (typical diameter 5 mm) were palpable 6 days after
subcutaneous implantation of A431 cancer cells in exponential
growth (1×106 cells per flank). TRF entrapped in Tf-vesicles, control
vesicles or in solution was administered by intravenous tail vein
injection (10 µg TRF per injection) once daily for 10 days. Animals
were weighed daily and tumor volume was determined by caliper
measurements (volume=d3×π/6). Results were expressed as rela-
tive tumor volume (rel. Voltx=Voltx /Volt0) and responses classified
analogous to Response Evaluation Criteria in Solid Tumors (RECIST,
[12]). Progressive disease is defined as an increase in relative tumor
volume higher than 1.2-fold, stable disease as a relative volume
between 0.7 and 1.2 of starting volume, partial response as measure-
able tumor with a reduction of more than 30% (0–0.7) and complete
response as the absence of any tumor.
2.5. Statistical analysis
Results were expressed as means±S.E.M. Statistical significance
was determined by one-way ANOVA followed by the Bonferroni post-
test (GraphPad Prism software). Differences were considered as
significant when P<0.05.
3. Results and discussion
3.1. Preparation and characterization of transferrin-bearing vesicles
encapsulating TRF
The formation of vesicles encapsulating TRF and bearing transfer-
rin (Tf-vesicles) was confirmed by TEM (Fig. 1A). TRF loading within
the vesicles was 28.5±1.9% of the initial TRF. However the
solubilization of TRF in palm oil or dimethylsulfoxide led to an
improved TRF loading of 30.8±0.6% and 44.1±0.6% respectively. TRF
will therefore be solubilized in dimethylsulfoxide prior further
preparations of vesicles. Transferrin was conjugated to the vesicles
at a level of 89±5% of the initial transferrin added, which corresponds
to an improvement compared to our previous conjugation rate of
around 50% [9,10]. Loaded Tf- and control vesicles respectively had a
z-average mean diameter of 137 nm (polydispersity: 0.169) and
123 nm (polydispersity: 0.154). As the cut-off size for extravasation
has been found to be 400 nm [13–15] for most tumors, this delivery
system has the required properties to access the receptor-expressing
tumor cells and specifically deliver TRF. Tf- and control vesicles were
bearing negative surface charges, slightly higher after conjugation of
the iron-saturated holo-transferrin (respectively −36 mV and
−40 mV for Tf-vesicles and control vesicles). These net negative
charges would reduce non-specific cellular uptake of the vesicles due
to a decrease of electrostatic interactions with the negatively charged
cellularmembrane [16]. To our knowledge, this is the first formulation
of tocotrienol entrapped in a targeted delivery system. The combina-
tion of active targeting (based on the use of Tf ligands) and passive
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targeting (based on the accumulation of particulate delivery systems
due to the enhanced permeability and retention) should provide a
tumor-selective targeting strategy.
3.2. Cellular uptake of TRF entrapped in Tf-bearing vesicles
The entrapment of TRF in the vesicles significantly improved TRF
uptake by the three cell lines compared to TRF solution (Fig. 1B): TRF
uptake after treatment with control vesicles was at least twice higher
than that of TRF solution for T98G and A2780 cell lines. The grafting of
transferrin on the vesicles further improved TRF uptake compared to
control vesicles: more than twice the amount of TRF was taken up by
A431 cells when treatedwith Tf-vesicles compared to control vesicles.
The highest amount of cell-associated fluorescence was found in A431
cells incubated with Tf-vesicles. TRF uptake was also qualitatively
confirmed using confocal microscopy in the three cell lines. Co-
Fig. 1. Preparation and characterization of transferrin-vesicles entrapping TRF. A) Transmission electron micrographs confirming the formation of vesicles entrapping TRF and
bearing Tf (Bar: 1 µm). B) Spectrofluorimetric quantification of the cellular uptake of TRF (10 µg/well) formulated as Tf-vesicles (green), control vesicles (orange) or as free drug
(red), in A431, T98G and A2780 cell lines (n=15)(*: p<0.05). C) Confocal laser scanning microscopy imaging of the cellular uptake of TRF (50 µg/dish) either entrapped in Tf-
vesicles, control vesicles or free in solution, after incubation for 4 h in A431, T98G and A2780 cells (red: nuclei stained with propidium iodide, blue: TRF) (magnification×40).
Table 1
Cytotoxicity of TRF, free or formulated as Tf-vesicles or control vesicles, in A431, T98G
and A2780 cells expressed as IC50 values (n=15).
Cell lines IC50 (μg/mL) (mean±S.E.M.)
Tf-vesicles Control vesicles Free TRF
A431 0.66±0.08 1.42±0.30 131.06±1.94
T98G 0.17±0.14 0.97±0.48 79.49±0.16
A2780 0.05±0.02 0.11±0.10 10.73±4.36
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localization of TRF in the nuclei was clearly visible in the three cell
lines treated with Tf-vesicles, with some accumulation in a central
compartment, possibly the nucleolus. The repartition of TRF within
the nuclei was particularly heterogeneous in A2780 cells. In A431
cells, TRF-derived fluorescence was also disseminated in the
Fig. 2. Cytotoxicity of TRF delivered as free drug (▲), entrapped in Tf-vesicles (■) or in
control vesicles (●), against (A) A431, (B) T98G and (C) A2780 cells (n=15).
Fig. 3. A) Tumor growth studies in a mouse A431 xenograft model after intravenous
administration of transferrin-vesicles encapsulating TRF (10 µg/injection) (green)
(controls: control vesicles encapsulating TRF (orange), TRF solution (red), untreated
tumors (black). Treatment was administered intravenously once daily on ten occasions.
Results were expressed as relative tumor volume (rel. Voltx=Voltx /Volt0) (n=5).
B) Variations of the animal body weight throughout the treatment regime (n=5).
C) Overall tumor response to treatments on the last injection day, stratified according
to change in tumor volume. D) Time to disease progression. Animals were removed
from the study once their tumor reached 12 mm diameter. (Color coding as in A).
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cytoplasm after treatment with Tf-vesicles. By contrast, cells treated
with control vesicles or free TRF showed no TRF-derived fluorescence,
except after treatment of A2780 cells with free TRF. In this case, a faint
TRF-derived fluorescence was observed in the cytoplasm, probably
due to the non-specific diffusion of the drug. These data demonstrated
that the entrapment of TRF in Tf-vesicles led to a significant
improvement of TRF uptake by the tested cell lines overexpressing
Tf receptors. Free TRF enters the cell by diffusion, while the vesicular
formulations are taken up by endocytosis, a comparatively slower but
highly specific process.
3.3. Cytotoxicity assay
The improvement of TRF uptake when administered in Tf-vesicles
led to similar improvement in the level of cytotoxicity of the various
formulations. The vesicle formulations of TRF were all significantly
more efficacious than the free drug by at least 80 times, with IC50
ranging from 0.05±0.02 to 1.42±0.30 µg/mL (Table 1, Fig. 2). The
grafting of transferrin to the vesicles further improved the therapeutic
efficacy of the vesicles entrapping TRF, by 5-fold for T98G cells and 2-
fold for A2780 and A431 cells. Although the highest TRF uptake was
found in A431 cells after treatment with Tf-vesicles, improved
cytotoxic activities were found in A2780 and T98G, probably because
A431 cells are more resistant than the two other cell lines. As
mentioned above, TRF consists of a mixture of tocotrienols and
tocopherols, but previous studies have demonstrated that its anti-
proliferative effects are mediated by tocotrienols only [17].
3.4. In vivo tumoricidal activity
In vivo, TRF entrapped in Tf-vesicles induced a measurable tumor
volume reductionwithin 24 h. Over the following 10 days, this led to a
marked regression of the tumors and improvement of the animal
survival, whereas none of the other treatments led to any tumor
regression. On the day of the last injection, 40% of tumors treated with
Tf-vesicles entrapping TRF were stable, while the remaining 60%
showed a partial response. By contrast, 100% of the tumors treated
with control vesicles or free TRF were progressive (Fig. 3). Although
the tumor grew after cessation of treatment, the rate of re-growth in
mice treated with Tf-vesicles was significantly lower than all other
treatment groups. As a result, the extended survival of the mice
treated with targeted vesicles, control vesicles and free TRF was
respectively 19 days, 12 days and 2 days compared to untreated mice.
Although a further extension of the number of injections to the
animals was currently not allowed, the extended survival results
obtained after 10 injections still demonstrated the superiority of Tf-
vesicles over the other formulations. The systemic use of TRF
entrapped in vesicles or administered as a solution was well tolerated
and no apparent signs of toxicity or significant weight loss were
observed (Fig. 3B).
The most striking effects of TRF entrapped in targeted vesicles was
the induction of tumor regressionwithin one day of treatment and the
near disappearance of the tumors for many animals of this treatment
group within 10 days of treatment, a duration generally acknowl-
edged as sufficient for treating minor ailments but not a cancer, even
with traditional chemotherapy. This therapeutic system was able to
act on subcutaneous implanted tumors after systemic administration
and should therefore have the potential to target multiple metastasic
nodules disseminated throughout the body. There may be scope to
further improve on the in vivo activity of these extremely safe delivery
systems, by using a higher dose, reducing the size of the vesicles and
extending the length of the treatment, hopefully leading to an
optimized therapeutic effect.
In conclusion, this work corresponds to the first preparation of a
tumor-targeted delivery system able to encapsulate tocotrienol.
Transferrin-conjugated vesicles showed a statistically significant uptake
advantage when compared to the non-targeted vesicles. The vesicle
formulations of tocotrienol significantly improved the therapeutic
efficacy of tocotrienol in vitro by at least 80 times compared to the
drug solution. The grafting of transferrin to the vesicles further
improved their therapeutic efficacy by at least 2-fold compared to
control vesicles. Our findings show that TRF encapsulated in transferrin-
bearing vesicles is a promising therapeutic system, leading to tumor
regression after intravenous administration without visible toxicity.
These studies provide a proof of principle that the entrapment of
vitamin E extract tocotrienol in a targeted delivery system may be an
attractive strategy for anti-tumor therapy, combining efficacy against
the tumor with the lowest possible effects on normal tissues and
organs after systemic administration.
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